Physician profile
Sarah Kassin
NPI 1205484219
$5,208.28
in general payments reported to CMS, 2019-2025
17 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $883 · 2022: $569 · 2023: $1,305 · 2024: $1,244 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,756.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $890.19 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $757.39 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $707.96 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $671.90 | 2021-2025 | Caplyta |
| Alkermes, INC. | $579.61 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $412.73 | 2021-2025 | Rexulti, Brintellix |
| Janssen Pharmaceuticals, INC | $383.84 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Vanda Pharmaceuticals INC. | $355.95 | 2021-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $160.53 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $81.91 | 2022-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $53.67 | 2022-2023 | Trintellix |
| Indivior INC. | $47.86 | 2023-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $29.58 | 2024 | Qelbree |
| Luye Pharma (USA) LTD. | $20.74 | 2025 | Erzofri Extended-Release |
| Idorsia Pharmaceuticals US INC | $18.83 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $18.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Kassin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.